Department of General Surgery, Coimbatore Medical College Hospital, Coimbatore, Tamil Nadu, India.
World J Surg Oncol. 2011 Feb 6;9:18. doi: 10.1186/1477-7819-9-18.
Breast cancer is a disease that continues to plague females during their entire lifetime. IL-6 and CRP are found to be elevated in various inflammatory and malignant diseases and their levels are found to correlate with the extent of the disease. The primary objective of this study was to determine the preoperative serum levels of IL-6 and CRP in breast carcinoma, and to correlate them with the staging of the disease and the prognosis.
59 female patients admitted for breast cancer were identified for the study and were subjected to thorough evaluation. Serum levels of IL-6 were assessed via Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was measured via immunoturbidimetry. Histological findings included tumour size, lymph node (LN) metastasis, and tumour staging. Relevant investigations were made to find out the presence of distant metastasis. Statistical analysis of the data was then processed.
Increases in cancer invasion and staging are generally associated with increases in preoperative serum IL-6 levels. IL-6 and CRP levels correlated with LN metastasis (P < 0.001, P < 0.001) and TNM stage (P < 0.001, P < 0.001). Tumour invasion and the presence of distant metastasis is associated with higher IL-6 levels (P = 0.001, P = 0.009). When we established the cutoff value for IL-6 level (20.55 pg/dl) by ROC curve, we noted a significant difference in overall survival (OS; P = 0.008). However, CRP evidenced no significance with regard to patient's OS levels. Serum IL-6 levels were correlated positively with CRP levels (r² = 0.579, P < 0.01)
Serum levels of IL-6 correlates well with the extent of tumor invasion, LN metastasis, distant metastasis and TNM staging thus enveloping all aspects of breast cancer.
乳腺癌是一种在女性整个生命周期中持续困扰她们的疾病。IL-6 和 CRP 在各种炎症性和恶性疾病中被发现升高，并且它们的水平与疾病的严重程度相关。本研究的主要目的是确定乳腺癌患者术前血清中 IL-6 和 CRP 的水平，并将其与疾病的分期和预后相关联。
本研究确定了 59 名因乳腺癌住院的女性患者，并对其进行了全面评估。通过酶联免疫吸附测定法（ELISA）评估血清中 IL-6 的水平，通过免疫比浊法测量 CRP 的水平。组织学发现包括肿瘤大小、淋巴结（LN）转移和肿瘤分期。进行了相关检查以确定是否存在远处转移。然后对数据进行了统计分析。
癌症侵袭和分期的增加通常与术前血清 IL-6 水平的升高相关。IL-6 和 CRP 水平与 LN 转移（P < 0.001，P < 0.001）和 TNM 分期（P < 0.001，P < 0.001）相关。肿瘤侵袭和远处转移的存在与更高的 IL-6 水平相关（P = 0.001，P = 0.009）。当我们通过 ROC 曲线确定 IL-6 水平的截断值（20.55 pg/dl）时，我们注意到总生存率（OS；P = 0.008）存在显著差异。然而，CRP 与患者的 OS 水平无显著相关性。血清 IL-6 水平与 CRP 水平呈正相关（r² = 0.579，P < 0.01）。
血清 IL-6 水平与肿瘤侵袭程度、LN 转移、远处转移和 TNM 分期密切相关，因此涵盖了乳腺癌的各个方面。
